Publications

Haematologica Early View

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Nature Leukemia

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Blood Cancer Journal

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Clinical and Translational Science

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

American Society of Hematology Annual Meeting

Correlation between Treatment-Emergent Cytopenias and Clinical Response with Imetelstat (IME) in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS): Analysis from the IMerge Trial

Long-Term Outcomes from Randomized, Double-Blind, Placebo-Controlled, Phase 3 IMerge Trial of Imetelstat for Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Correlation between Interleukin (IL)-8 and Tumor Necrosis Factor (TNF)-Alpha Levels and Overall Survival in Patients (Pts) with Myelofibrosis (MF) Relapsed or Refractory (R/R) to a Janus-Associated Kinase Inhibitor (JAKi) Treated with Imetelstat (IME) in the IMbark Trial

IMproveMF: Phase 1b Trial of Imetelstat Plus Ruxolitinib in Patients with Intermediate-2 or High-Risk Myelofibrosis

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-based Therapy: Interim Analysis Results of the IMpress Study

British Journal of Haematology

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

Future Oncology

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people withlower-risk myelodysplastic syndromes and anemia

SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO) ANNUAL MEETING

IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy in Patients With Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitors

Outcomes of Imetelstat Therapy in Patients With Ring Sideroblast–Negative Lower-Risk Myelodysplastic Syndromes From the Pooled IMerge Study Populations

Outcomes With Imetelstat by Serum Erythropoietin Levels in Patients With Lower-Risk Myelodysplastic Syndromes Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents

Journal of the Advanced Practitioner in Oncology

Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes and Anemia

European Hematology Association Annual Congress

Health-Related Quality of Life Outcomes In Patients with Lower-Risk Myelodysplastic Syndromes Treated with Imetelstat In the Imerge Trial

Outcomes with Imetelstat by Serum Erythropoietin Levels In Patients with Lower-Risk Myelodysplastic Syndromes Who Were Treatment Naive or Who Had Prior Treatment with Erythropoiesis-Stimulating Agents

Outcomes of Imetelstat Therapy In Patients with Ring Sideroblast-Negative Lower-Risk Myelodysplastic Syndromes From The Pooled Imerge Study Populations

Increased Duration Of Time Without Transfusion Reliance (TWITR) For Patients With Lower-Risk Myelodysplastic Syndromes Treated With Imetelstat Versus Placebo In the Imerge Trial